G1 Therapeutics Completes Leadership Team With Appointment Of Raj Malik, MD, Chief Medical Officer And Greg Mossinghoff, Chief Business Officer

RESEARCH PARK TRIANGLE, N.C., June 17, 2014 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc., a privately held pharmaceutical company that focuses on the discovery and development of novel small molecules for use in cancer therapy and biodefense applications, today announced that Raj Malik, MD, has joined the company as Chief Medical Officer and Greg Mossinghoff has been named Chief Business Officer. Dr. Malik will oversee the advancement of the company's lead CDK 4/6 inhibitor, G1T28-1, into a Phase I study for the reduction of chemotherapy-induced myelosuppression in the third quarter of this year. Mr. Mossinghoff will assume responsibility for G1's finances and business development efforts.

Help employers find you! Check out all the jobs and post your resume.